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Because matrix metalloproteinases (MMPs) play roles
in inflammatory tissue injury, we asked whether MMP
secretion by gastric epithelial cells may contribute to
gastric injury in response to signals involved in Helico-
bacter pylori-induced inflammation and/or cyclooxyge-
nase inhibition. Tumor necrosis factor (TNF)-, inter-
leukin (IL)-1, and epidermal growth factor (EGF)
stimulated gastric cell MMP-1 secretion, indicating that
MMP-1 secretion occurs in inflammatory as well as non-
inflammatory situations. MMP-1 secretion required ac-
tivation of the MAPK Erk and subsequent protein syn-
thesis but was down-regulated by the alternate MAPK,
p38. In contrast, secretion of MMP-13 was stimulated by
TNF-/IL-1 but not EGF and was Erk-independent and
mediated by p38. MMP-13 secretion was more rapid
(peak, 6 h) than MMP-1 (peak >30 h) and only partly
depended on protein synthesis, suggesting initial re-
lease of a pre-existing MMP-13 pool. Therefore, MMP-1
and MMP-13 secretion are differentially regulated by
MAPKs. MMP-1 secretion was regulated by E prosta-
glandins (PGEs) in an Erk-dependent manner. PGEs en-
hanced Erk activation and MMP-1 secretion in response
to EGF but inhibited Erk and MMP-1 when TNF- and
IL-1 were the stimuli, indicating that the effects of
PGEs on gastric cell responses are context-dependent.
These data show that secretion of MMPs is differentially
regulated by MAPKs and suggest mechanisms through
which H. pylori infection and/or cyclooxygenase inhibi-
tion may induce epithelial cell signaling to contribute to
gastric ulcerogenesis.
Whereas peptic ulcer disease (PUD)1 affects millions of pa-
tients in the United States each year (1), gastric inflammation
is even more prevalent and predisposes to both PUD and ade-
nocarcinoma of the stomach (2). Two major risk factors for
gastritis and PUD are gastric colonization with Helicobacter
pylori and nonsteroidal anti-inflammatory drug (NSAID) use
(3–5). H. pylori colonizes more than half of the world’s popula-
tion. Eradication of H. pylori results in resolution of gastric
inflammation, confirming its central role in pathogenesis (6).
H. pylori-associated PUD is accompanied by tissue inflamma-
tion and secretion of cytokines, including interleukin (IL)-1
and tumor necrosis factor (TNF)- (7–12). Nevertheless, the
mechanisms through which H. pylori induces gastric damage
are not well established (5).
Matrix metalloproteinases (MMPs) are zinc-coordinating en-
zymes that remodel healthy connective tissue by specifically
digesting collagen and other structural molecules (13, 14). In
chronic inflammatory conditions, such as rheumatoid arthritis,
the extracellular secretion of MMPs substantially contributes
to stromal tissue destruction (15–21). Either directly or indi-
rectly (via induction of cytokine synthesis),H. pylori stimulates
gastric epithelial cells to produce MMPs in vitro (10, 22–27).
Thus, H. pylori colonization may influence gastric cells to pro-
mote inflammation (5) and damage the gastric mucosa.
In contrast, NSAID-induced PUD is accompanied by rela-
tively little inflammation (28). NSAIDs are presumed to dam-
age the gastric mucosa by inhibiting cyclooxygenase and de-
pleting E prostaglandins (PGEs). PGEs regulate gastric blood
flow and production of bicarbonate and mucus; thus, down-
regulated PGE synthesis may impair barrier function of the
gastric mucosa (29). Conversely, replenishment of PGEs using
the synthetic PGE analog misoprostal reduces the gastrotoxic-
ity of NSAIDs (30). The possibility that prostaglandins directly
regulate gastric cell function has not been rigorously examined,
despite complex effects on signal transduction exerted by PGEs
in many cell types (20, 31–35).
Mitogen-activated protein kinases (MAPKs) are serine/thre-
onine protein kinases including the extracellular signal-regu-
lated kinase (Erk), JNK, and p38 subfamilies (36). Whereas
p38 and Jnk are implicated in inflammatory responses (37, 38),
Erk has been regarded as a signal for cell growth and differ-
entiation. However, Erk also may regulate inflammatory and
tissue-destructive responses (20, 39). In fibroblast-like synovio-
cytes, which largely drive the destruction of cartilage in rheu-
matoid arthritis (16, 17, 21), Erk regulates MMP-1 secretion in
response to inflammatory cytokines (20). PGEs inhibit fibro-
blast-like synoviocyte secretion of MMP-1 via inhibition of Erk
(15, 20, 40). This model suggests that autodestruction of stro-
mal tissue in response to inflammatory stimuli may be medi-
ated by MMP production and regulated by MAPKs and
prostaglandins.
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In the present study, we examined gastric epithelial cell
responses to signals relevant to exposure to H. pylori and to
NSAIDs. We asked whether cytokine stimulation of gastric
epithelial cells regulates MMP secretion and whether such
regulation is MAPK- and/or prostaglandin-dependent. Our ob-
servations suggest a model in which gastric ulceration is prop-
agated by the transduction of exogenous pro-inflammatory sig-
nals into the gastric cells themselves and by a gastric cell
response that may result in autologous destruction of gastric
tissue.
EXPERIMENTAL PROCEDURES
Materials—Unless otherwise stated, all materials were from Sigma.
Anti-phospho-Erk, anti-Erk 1, anti-Erk 2, and anti-p38 antisera, as
well as horseradish peroxidase-conjugated anti-rabbit antiserum, were
from Santa Cruz Biotechnology. Anti-MMP-1 and anti-MMP-13 anti-
sera were from Chemicon. 10% Tris-glycine/polyacrylamide gels were
from Novex/Invitrogen. UO126, PD98059, and SB203580 were from
Biomol. SB202190 was from Calbiochem. Centricon™ centrifugal filter
devices were from Millipore. RPMI 1640 medium, fetal bovine serum,
and 2.5% trypsin/EDTA were from BioWhittaker. Penicillin G sodium
(10,000 units/ml)/streptomycin sulfate (10,000 g/ml) in 0.85% NaCl
was from Invitrogen. ECL chemiluminescence kit was from Amersham
Biosciences. AGS cells were from the American Type Culture Collec-
tion. MMP-1 and MMP-13 activity kits were from R and D Systems.
Cell Culture and Cell Treatment—AGS human cells derived from a
gastric epithelial tumor (41) were cultured in 6-well plates in RPMI
1640 medium containing 10% fetal bovine serum and penicillin/strep-
tomycin. Cells grown to near confluence were serum-starved for 24 h
(0% fetal bovine serum) before stimulation and/or other treatment.
Unless otherwise specified, the following concentrations of reagents
were used: IL-1, TNF-, and epidermal growth factor (EGF), 20 ng/ml
each; PGE1, PGE2, UO126, SB203580, and SB202190, 10 M each;
PD98059, 50 M; and cycloheximide, 10 g/ml.
Erk and p38 Phosphorylation and Activation—Erk activation was
defined as the degree of phosphorylation of the activating tyrosine and
threonines on Erk 1 and 2, as determined by immunoblotting with
anti-phospho-Erk antiserum. Similarly, p38 activation was defined as
p38 phosphorylation usng anti-phospho-p38 antiserum. AGS cells were
serum-starved for 24 h, followed by experimental treatment. Lysates
were prepared as described, protein levels were measured, and equiv-
alent amounts of protein were subjected to SDS-PAGE analysis and
immunoblotting for the phosphorylated, active forms of Erk (20). Im-
munoblots imaged by chemiluminescence and autoradiography were
quantitated by densitometry. Duplicate samples were immunoblotted
for total Erk1/2 or p38, and Erk and p38 activation was reported as
phosphorylated/total protein. Because the actual units of quantitation
were arbitrary, results were normalized to either the unstimulated or
maximally stimulated condition, as appropriate.
MMP Secretion—MMP secretion was determined as described pre-
viously (20). Briefly, after AGS cells were grown to near confluence and
serum-starved for 24 h, supernatants were removed and replaced with
fresh medium. After a 30–60-min period for equilibration, the cells
were stimulated, and the supernatants were recovered and concen-
trated in Centricon™ centrifugal filter devices (Mr cutoff, 30,000) for 35
min at 5000 g at 4 °C. Aliquots of the concentrated supernatants were
supplemented with Laemmli buffer and assayed for MMP-1 and
MMP-13 by SDS-PAGE and immunoblotting with appropriate anti-
MMP antisera (1:200 dilution) and horseradish peroxidase-conjugated
anti-rabbit antibody. Visualization and quantitation were as described
for Erk. Measurement of secretion of active MMP-1 and MMP-13 was
performed using commercially available kits, according to the manu-
facturer’s instructions.
RESULTS
MMP-1 and MMP-13 Secretion Stimulated by TNF-, IL-1,
and EGF—We first examined whether AGS cell stimulation
could induce MMP-1 secretion. TNF-, IL-1, or both (18 h)
induced MMP-1 secretion (Fig. 1, A, top panel, and B). Because
TNF-/IL-1 together induced more MMP-1 secretion than
either alone (TNF-/IL-1 versus TNF-, p  0.03; TNF-/
IL-1 versus IL-1, p  0.05) and because both cytokines are
implicated in gastrointestinal ulcerogenesis (7–12, 42, 43),
most subsequent experiments were performed using TNF-/
IL-1 together. Significant TNF-/IL-1 stimulation of MMP-1
secretion was first observed after 12 h, and MMP-1 continued
to accumulate for at least 30 h (Fig. 1C). EGF also stimulated
MMP-1 secretion (Fig. 1A, top panel, and B). MMP-1 secretion
in response to EGF was also delayed (12 h after stimulation),
and MMP-1 continued to accumulate for 24 h (Fig. 1C). These
data confirm that AGS cell MMP-1 secretion is responsive to
both inflammatory cytokines and growth factors. Moreover,
MMP-1 secreted in response to both EGF and TNF-/IL-1 was
enzymatically active (Fig. 1D).
FIG. 1. Effects of EGF, TNF-, and
IL-1 on MMP-1 and MMP-13 secre-
tion by AGS cells. A and B, AGS cells
were serum-starved for 24 h; stimulated
for 18 h  EGF, TNF-, and/or IL-1
(each at 20 ng/ml); and assayed for
MMP-1 (A and B) or MMP-13 (A and B)
secretion as described under “Experimen-
tal Procedures.” C, time course. AGS cells
were stimulated  EGF or TNF-/IL-1
and assayed for MMP-1 and MMP-13 se-
cretion. D, activation state of secreted
MMPs. AGS cells stimulated  EGF or
TNF-/IL-1 were assayed for active
MMP-1 and MMP-13 by an enzyme-
linked immunosorbent assay-based
method. Data shown are representative
or the mean  S.E. of three experiments.
*, p  0.05; **, p  0.06; ***, p  0.08
(versus the appropriately matched condi-
tion, either no treatment (B and D) or t 
0 (C)).
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TNF-/IL-1 also significantly stimulated secretion of enzy-
matically active MMP-13 (Fig. 1A, bottom panel, B, and D).
TNF-, but not IL-1 alone, also increased MMP-13 secretion.
MMP-13 secretion occurred in response to TNF-/IL-1 as
early as 1 h after stimulation and reached steady-state levels
more rapidly (6 h) than MMP-1 (Fig. 1C). In contrast to
MMP-1, EGF did not stimulate MMP-13 secretion (Fig. 1A,
bottom panel, and B). Therefore, AGS cell MMP-1 and MMP-13
expression, secretion, and activity are differentially regulated
in a stimulus-specific manner.
Role of Protein Synthesis in MMP-1 and MMP-13 Secretion—
The differing kinetics of MMP-1 and MMP-13 secretion sug-
gested that these MMPs might differ with regard to a require-
ment for protein synthesis. To evaluate this possibility, we
tested the effects of cycloheximide (CHX), which inhibits pro-
tein synthesis by affecting binding and activity of transfer RNA
(44). CHX almost completely inhibited MMP-1 secretion in
response to both EGF (Fig. 2A) and TNF-/IL-1 (Fig. 2B),
confirming the dependence of MMP-1 secretion on protein syn-
thesis. In contrast, MMP-13 secretion after 1 h was almost
entirely insensitive to CHX treatment (Fig. 2C), and MMP-13
secretion after 18 h was only partly inhibited (Fig. 2B), sug-
gesting initial release of pre-formed MMP-13, followed by later
secretion of newly synthesized protein. These data provide
further evidence that secretion of MMP-1 and MMP-13 is dif-
ferentially regulated.
Erk Regulates MMP-1 but not MMP-13 Expression by Gastric
Epithelial Cells—Because EGF, a canonical activator of Erk
(45), stimulated MMP-1 secretion from AGS cells, we next
asked whether Erk regulates MMP-1. EGF stimulation of AGS
cells induced rapid but transient activation of Erk (peak at
15–30 min), with return to baseline by 4 h. TNF-/IL-1 also
stimulated transient Erk activation, with similar kinetics (Fig.
3AC). Thus, in both cytokine- and EGF-stimulated AGS cells,
Erk activation and return to baseline activity precede MMP-1
secretion. Consistent with the effects of cytokines on MMP-1
secretion, TNF-/IL-1 stimulated greater Erk activation than
either cytokine alone.
To determine whether Erk activation is required for MMP-1
expression, we tested the effects of UO126 (46), a specific in-
hibitor of MEK, the proximal activator of Erk (47). UO126
inhibited both EGF- and TNF-/IL-1-stimulated Erk activa-
tion, as well as MMP-1 secretion (Fig. 4A and B). PD98059,
another specific MEK inhibitor (48), also inhibited both Erk
activation and MMP-1 secretion in response to EGF or TNF-/
IL-1 (data not shown). Taken together, these studies confirm
that Erk activation mediates MMP-1 secretion from AGS cells
in response to either EGF or TNF-/IL-1.
TNF-/IL-1-stimulation of MMP-13 secretion after 18 h
was not significantly inhibited by UO126 (Fig. 4B) or PD98059
(data not shown). MMP-13 secretion after 1 h of TNF-/IL-1
stimulation was also not inhibited by UO126 (data not shown).
Thus, Erk activity appears not to regulate either the protein
synthesis-dependent or synthesis-independent components of
MMP-13 secretion. This observation is consistent with the fail-
ure of EGF to stimulate MMP-13 secretion.
Erk Activation Is an Early Event in MMP-1 Secretion—The
observation that Erk activation returned to baseline hours
before detectable MMP-1 secretion (Fig. 3C) suggested that Erk
activation is an early step leading to MMP-1 secretion. To test
this hypothesis, we exposed AGS cells to UO126 before or after
EGF or TNF-/IL-1 stimulation. Incubation of AGS cells with
UO126 prior to stimulation resulted in expected inhibition of
MMP-1 secretion (Fig. 5), but adding UO126 90 min after EGF
or TNF-/IL-1 stimulation resulted in little or no inhibition of
MMP-1 secretion. Thus, Erk activation initiates a process lead-
ing to MMP-1 secretion, but continual Erk activity is not
required.
p38 Activity Inhibits MMP-1 Secretion via Inhibition of
Erk—Because p38 activity typically promotes inflammatory
phenotypes (49, 50), we hypothesized that p38 would positively
regulate MMP secretion and, conversely, that its inhibition
would abrogate secretion. We first confirmed that TNF-/IL-1
transiently stimulated p38 phosphoactivation in AGS cells
(Fig. 3D). In contrast, EGF only marginally stimulated p38 in
these experiments. Unexpectedly, the specific p38 inhibitor
SB203580 (51) enhanced MMP-1 secretion in AGS cells stimu-
lated with either EGF or TNF-/IL-1 (Fig. 4, A and B).
SB202190, another selective p38 inhibitor (52), had similar
effects (data not shown). SB203580 (Fig. 4, A and B), as well as
SB202190 (data not shown), also enhanced Erk activation in
response to either EGF or TNF-/IL-1. Thus, the effects of p38
inhibition on MMP-1 secretion and Erk activation were con-
cordant. The observations that SB203580 alone stimulated Erk
activation and MMP-1 secretion and that both of these pro-
cesses were inhibited by UO126 (Fig. 4D) indicate that p38
tonically inhibits Erk activity and MMP-1 secretion, regardless
FIG. 2. CHX sensitivity of MMP-1 and MMP-13 secretion. A and
B, AGS cells were incubated for 30 min CHX (10 g/ml), stimulated
EGF (A) or TNF-/IL-1 (B) for 18 h, and assayed for MMP-1 (A and B)
and MMP-13 (B) secretion. C, AGS cells were incubated for 30 min 
CHX followed by TNF-/IL-1 stimulation for 1 h and assay of MMP-13
secretion. Data shown are the mean  S.E. of three (A) or four (B and
C) experiments. *, p  0.05 (versus the appropriate stimulated
condition).
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of cell stimulation status, and that its inhibitory action on
MMP-1 is mediated, at least in part, via Erk inhibition.
In contrast to the enhancing effects of p38 inhibitors on Erk
and MMP-1, both SB203580 (Fig. 4B) and SB202190 (data not
shown) inhibited both p38 phosphoactivation and MMP-13 se-
cretion in AGS cells stimulated with TNF-/IL-1. These stud-
ies show that p38 provides a positive signal for MMP-13 secre-
tion, further evidence that MMP-1 and MMP-13 expression is
differentially regulated by MAPKs in AGS cells. The observa-
tion that SB203580 failed to inhibit the early, CHX-independ-
ent phase of MMP-13 secretion (Fig. 4C) indicates that p38
regulates the later, protein synthesis-dependent phase of
MMP-13 secretion.
PGEs Regulate Erk Activation and MMP-1 but not MMP-13
Secretion in Gastric Cells—Because PGEs inhibit both Erk and
MMP-1 responses in other cell types (15, 20, 34, 35, 40, 53, 54),
we asked whether they would affect AGS cells. Preincubation of
AGS cells with PGE1 or PGE2 enhanced both Erk activation
and MMP-1 secretion in response to EGF (Fig. 6A). In contrast,
PGE1 and PGE2 inhibited Erk activation and MMP-1 secretion
in cells stimulated with TNF-/IL-1- (Fig. 6B). In the absence
of other stimuli, PGE1 and PGE2 independently stimulated
both Erk phosphorylation (Fig. 6C) and MMP-1 secretion (Fig.
6D), and PGE-stimulated MMP-1 secretion was inhibited by
UO126. In total, these studies demonstrate that PGEs exert
stimulus-specific effects on Erk and MMP-1 in AGS cells and
that the capacity of PGEs to independently induce MMP-1
secretion depends upon their ability to activate Erk. In con-
trast, neither PGE1 nor PGE2 significantly inhibited TNF-/
IL-1--stimulated MMP-13 secretion, consistent with the ob-
FIG. 3. Effects of EGF, TNF-, and
IL-1 on Erk and p38 activation in
AGS cells. A and B, AGS cells were incu-
bated for 30 min EGF, TNF-, IL-1, or
TNF-/IL-1 (each at 20 ng/ml), and ly-
sates were assayed for Erk activation as
described under “Experimental Proce-
dures.” A: top panel, immunoblot for phos-
phorylated Erk; bottom panel, immuno-
blot for total Erk. B, Erk phosphorylation
normalized to total Erk levels. C and D,
time courses of MAPK activation. AGS
cells were stimulated with EGF or TNF-
/IL-1, followed by determination of Erk
activation (C) or p38 activation (D), each
normalized to total enzyme levels. Data
shown are representative (A) or the
mean S.E. (BD) of five experiments. *,
p  0.05; **, p  0.07 (versus appropriate
control, either no treatment (B) or t  0
(C)).
FIG. 4. Erk and p38 differentially
regulate MMP-1 and MMP-13. AGS
cells were incubated for 30 min with
UO126 or SB203580 (10 M each) fol-
lowed by stimulation with EGF (A) or
TNF-/IL-1 (B) and assay for Erk or p38
activation (30-min stimulation), as well
as MMP-1 or MMP-13 secretion (18-h
stimulation). C, AGS cells were incu-
bated  SB203580 (10 M, 30 min) fol-
lowed by a 60-min stimulation with TNF-
/IL-1 and determination of MMP-13
secretion. D, AGS cells were incubated 
SB203580, UO126, or both and assayed
for Erk activation (30-min incubation) or
MMP-1 secretion (18-h incubation). Data
shown are the mean  S.E. of three (A,
MMP-1; B, Erk; and D), five (B, MMP-13;
C), six (B, MMP-1), or seven (A, Erk) ex-
periments for each condition. *, p  0.05;
**, p  0.06; NS, not significant (all ver-
sus stimulated condition).
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servation that MMP-13 secretion is Erk-independent
(inhibition of TNF-/IL-1--stimulated MMP-13 secretion:
PGE1, 27  24%, p  0.19; PGE2, 29  22%, p  0.15).
DISCUSSION
The pathogenesis of peptic ulcer disease is not well under-
stood. We considered whether MMP secretion from host cells
might contribute to gastric tissue stromal destruction because
MMPs have analogous roles in other inflammatory diseases
such as rheumatoid arthritis (19, 20). Gastric epithelia secrete
active MMPs including MMP-2, -3, -7, and -9 (10, 22–25, 27),
but MMP regulation has not been well explored. We selected
MMP-1 and MMP-13 to study because prior observations in
other cell types have indicated that these MMPs are differen-
tially regulated by MAPKs and therefore likely to exhibit con-
trasting properties (20, 43, 55, 56). Basement membrane is
typically composed primarily of type IV collagen (57), which is
not a major substrate for MMP-1. However, type I and type III
collagens predominate in the gastric stroma (58) and are sus-
ceptible to both MMP-1 and MMP-13 (59). In a rat model of
gastric ulceration, mRNAs for type I collagen also were up-
regulated (60). The observation that arteries and veins employ
types I, II (also susceptible to MMP-1) (59), and III collagen in
their matrices (61) suggests that MMP-1 might also contribute
to hemorrhage in ulcer disease. Gastric cells have previously
been shown to secrete MMP-1 in a manner consistent with
their ability to invade stroma. For example, Go¨o¨z et al. (24)
reported that H. pylori infection results in MMP-1 secretion
from AGS cells, and we recently observed that H. pylori stim-
ulates AGS cell MMP-1 secretion in an Erk-dependent man-
ner.2 Similarly, MMP-1 production is increased in human gas-
tric carcinomas (62). Membrane type-1 MMP shares with
MMP-1 the capacity to degrade type I collagen (63) and has
been implicated in invasiveness of gastric carcinoma cells (64).
Thus, it is likely that MMP-1 plays a role in ulcerogenesis,
perhaps in conjunction with other MMPs that are secreted from
gastric cells in active forms and target other collagen types
(65). To our knowledge, ours is the first demonstration that
gastric cells also secrete MMP-13.
Secretion of both MMP-1 and MMP-13 by AGS cells was
stimulated by inflammatory cytokines. Because H. pylori in-
duces IL-1 and TNF- secretion in ulcers and gastritis (24,
66), these data implicate cytokine induction as a mechanism in
infectious ulcer formation. The observation that MMP-13 se-
cretion was stimulated by TNF- and IL-1, but not EGF,
contrasts with MMP-1, which responded to all three, demon-
strating that MMP-1 and MMP-13 are differentially regulated
in AGS cells. The response of MMP-1 secretion to both a growth
factor and cytokines suggests that MMP-1 may participate in
homeostatic connective tissue remodeling, as well as in inflam-
mation-induced injury. In contrast, MMP-13 is more likely to
play a role solely in inflammatory responses.
Similarly, the kinetics of MMP-1 and MMP-13 secretion in
response to TNF-/IL-1 differed markedly. Delayed (12 h),
CHX-inhibitable MMP-1 secretion indicates a requirement for
protein synthesis, presumably of MMP-1 itself. MMP-13 secre-
tion at 12 h also was partly CHX-inhibitable, but an early (1 h),
CHX-insensitive component of MMP-13 secretion suggests a
two-phase process: initial, rapid release of a pre-existing
MMP-13 pool, followed by de novo MMP-13 synthesis.
MMP-1 and MMP-13 are differentially regulated by MAPKs
in fibroblast-like synovial cells (20, 55), and we now show their
differential regulation by MAPKs in AGS cells. Erk regulates
MMP-1 secretion in response to either EGF or TNF-/IL-1,
but persistent Erk activation is not required because Erk in-
hibitors were not effective when added after peak Erk activity.
The observation that Erk activation was not inhibited by CHX
(data not shown) confirms that Erk activation precedes protein
synthesis in the MMP response. The effects of Erk on MMP-1
synthesis likely are mediated, at least in part, through AP-1
transcriptional activation (67). In contrast, Erk did not regu-
late either the initial release of pre-formed MMP-13 from AGS
cells or the subsequent synthesis of additional MMP-13. The
observation that EGF (a canonical activator of Erk) did not
stimulate MMP-13 secretion confirms that MMP-13 secretion
is Erk-independent and differentially regulated compared with
MMP-1 secretion.
In contrast to Erk, p38 activity inhibits AGS cell MMP-1
secretion, as deduced from the observation that p38 inhibitors
enhanced release of MMP-1. These observations were unex-
pected because p38 is generally considered pro-inflammatory,
and p38 inhibitors are under study as anti-inflammatory
agents (68–70). Studies in keratinocytes and dermal fibro-
blasts have implicated p38 as positively regulating MMP-1
secretion (71–74); however, the effects of p38 on MMP-1 secre-
tion are clearly cell type-specific because p38 inhibition has no
effect on MMP-1 secretion from synovial fibroblasts (20, 75). In
gastric cells, the observation that SB203580 enhanced both Erk
and MMP-1 secretion in a UO126-inhibitable manner indicates
that p38 acts by inhibiting Erk. This observation is not without
precedent because p38 down-regulates and SB203580 stimu-
lates Erk activity and Erk-mediated proliferation in another
human gastrointestinal tumor epithelial cell line, pancreatic
cells (76). The mechanism of p38-mediated Erk inhibition
might relate to high level selectivity of distinct MAPK phos-
phatases for Erk and p38 (77). The ability of p38 inhibitors to
stimulate and/or enhance gastric cell MMP-1 release suggests
that they may prove ulcerogenic, consistent with a role for p38
in gastric and oral mucosal healing in humans and rats (78,
79). However, in contrast to MMP-1, the ability of p38 inhibi-
tors to inhibit MMP-13 secretion suggests that MMP-13 secre-
tion is positively regulated by p38. The net effect of p38 inhi-
bition on gastric mucosal homeostasis may therefore depend on
the balance between these two and probably other activities.
The observation that p38 inhibition of MMP-1 secretion is
Erk-dependent again points to Erk as a central regulator of
MMP-1.
PGEs improve gastric barrier functions by increasing blood
flow, mucus and bicarbonate secretion, and gastric epithelium
proliferation while decreasing acid secretion (29). Our data
2 M. H. Pillinger, N. Marjanovic, S.-Y. Kim, J. U. Scher, P. Izmirly, S.
Tolani, V. Dinsell, Y.-C. Lee, M. J. Blaser, and S. B. Abramson, unpub-
lished observations.
FIG. 5. Kinetics of Erk regulation of MMP-1 in AGS cells. AGS
cells were incubated  10 M UO126 30 min before, 30 min after, or 90
min after addition of EGF or TNF-/IL-1. Stimulation was continued
for a total of 18 h, and the supernatants were analyzed for MMP-1
secretion. Data shown are the mean  S.E. of three experiments for
each condition. *, p  0.05 versus the stimulated condition without
inhibitors; **, p  0.07; NS, not significant versus stimulated condition.
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suggest an additional role: regulation of auto-catabolic pro-
cesses such as MMP-1 secretion. However, MMP-1 secretion
can be either enhanced or inhibited by PGEs, depending on the
stimulus involved. Thus, the actual effects of PGEs on gastric
barrier maintenance in vivo may vary with context, and the
notion that PGEs are gastroprotective may be an oversimplifi-
cation. Alternatively, it is possible that both stimulation and
inhibition of MMP-1 secretion by PGEs are salutary with re-
spect to gastric homeostasis. PGEs may serve to stimulate low
levels of MMP-1 secretion in the absence of inflammation (or in
the presence of growth factors) to facilitate its role in normal
tissue remodeling (80), but they may act to inhibit destructive
MMP-1 secretion induced by inflammatory cytokines. Both the
enhancing and inhibiting effects of PGEs on MMP-1 appear to
be Erk-dependent. Although the mechanism(s) by which PGEs
can both stimulate and inhibit Erk activation and MMP-1
expression is not clear, four PGE receptors (EP1–EP4) have
been identified (81–83), and their differential engagement may
promote divergent effects. Alternatively, PGEs might induce a
single signal that can modulate distinct pathways, depending
upon the specific activation state of the cell.
In summary, our data indicate that MMP secretion by gas-
tric epithelial cells may be driven by both cytokines and EGF
and implicate Erk and p38, as well as PGEs, as important
regulators (Fig. 7). These observations suggest mechanisms by
which gastric cells may participate in the propagation of gastric
inflammation and ulcer disease in specific contexts, such as in
H. pylori-induced inflammation and/or cyclooxygenase inhibi-
tion. This work opens possible pharmacologic avenues to min-
imize ulcer risk or to treat peptic ulceration.
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